Cel Sci CVM
NYSE CVM
$1.61 +0.01 (+0.62%)
At close: Oct 22, 2026 · 4:00 PM EDT

Cel Sci (CVM) Amortization of Deferred Charges (2017 - 2018)

Updated

Analysis

Cel Sci (CVM) Amortization of Deferred Charges (2017 - 2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 Cel Sci 2.91 Mn -22.74 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2018 933,340.00
Mar 31, 2018 411,367.00
Dec 31, 2017 611,717.00
Sep 30, 2017 2.12 Mn
Jun 30, 2017 -1.21 Mn
API Access

Cel Sci Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=CVM&period=max&api_key=YOUR_API_KEY